Cerenis Adds $13.9M to C Round


Cerenis Therapeutics, a biotech based in Ann Arbor, MI and Toulouse, France, said today that it has raised an additional $13.9 million in its Series C funding round. The first closing of the round was announced in July. The new capital, which came from the investment group IRDI-IXO and undisclosed private investors, brings the Series C round to $69.7 million and the total amount the firm has raised to $162.9 million, according to the company and based on today’s exchange rate between the Euro and the U.S. dollar. The company plans to use the third-round financing to fund a Phase II trial of its lead drug, CER-001, for cardiovascular disease. Its previous investors include Ann Arbor’s EDF Ventures, France’s Fund for Strategic Investment, Sofinnova Partners, HealthCap, Alta Partners, TVM Capital, OrbiMed Advisors, and Daiwa Corporate Investment.

By posting a comment, you agree to our terms and conditions.